Research programme: cancer therapeutics and antibiotics - Sanofi/Warp Drive Bio

Drug Profile

Research programme: cancer therapeutics and antibiotics - Sanofi/Warp Drive Bio

Alternative Names: RAS gene inhibitors - Sanofi/Warp Drive Bio

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Warp Drive Bio
  • Developer Sanofi; Warp Drive Bio
  • Class Small molecules
  • Mechanism of Action Ras gene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Gram-negative infections

Most Recent Events

  • 30 Aug 2016 Warp Drive Bio has patent protection for Small Molecule-Assisted Receptor Targeting (SMART) technology in USA
  • 11 Jan 2016 Early research in Gram-negative infections in USA (unspecified route)
  • 11 Jan 2016 Sanofi and Warp Drive Bio extend and reshape collaboration to develop cancer therapeutics and antibiotics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top